FOLFOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases

Detalles Bibliográficos
Autores principales: Antoniotti, Carlotta, Vetere, Guglielmo, Cremolini, Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577793/
https://www.ncbi.nlm.nih.gov/pubmed/36267710
http://dx.doi.org/10.21037/atm-22-3656
_version_ 1784811838944313344
author Antoniotti, Carlotta
Vetere, Guglielmo
Cremolini, Chiara
author_facet Antoniotti, Carlotta
Vetere, Guglielmo
Cremolini, Chiara
author_sort Antoniotti, Carlotta
collection PubMed
description
format Online
Article
Text
id pubmed-9577793
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-95777932022-10-19 FOLFOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases Antoniotti, Carlotta Vetere, Guglielmo Cremolini, Chiara Ann Transl Med Editorial AME Publishing Company 2022-09 /pmc/articles/PMC9577793/ /pubmed/36267710 http://dx.doi.org/10.21037/atm-22-3656 Text en 2022 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Editorial
Antoniotti, Carlotta
Vetere, Guglielmo
Cremolini, Chiara
FOLFOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases
title FOLFOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases
title_full FOLFOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases
title_fullStr FOLFOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases
title_full_unstemmed FOLFOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases
title_short FOLFOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases
title_sort folfoxiri plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577793/
https://www.ncbi.nlm.nih.gov/pubmed/36267710
http://dx.doi.org/10.21037/atm-22-3656
work_keys_str_mv AT antoniotticarlotta folfoxiriplusbevacizumabinthetreatmentofmetastaticcolorectalcancerpatientswithunresectablelivermetastases
AT vetereguglielmo folfoxiriplusbevacizumabinthetreatmentofmetastaticcolorectalcancerpatientswithunresectablelivermetastases
AT cremolinichiara folfoxiriplusbevacizumabinthetreatmentofmetastaticcolorectalcancerpatientswithunresectablelivermetastases

Ejemplares similares